AB Science

<!-- Name:DistributionId Value:1000798290 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:1000797840 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:1000795170 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

<!-- Name:DistributionId Value:1000780029 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4577 -->…

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS Paris, December 29 2022, 6pm CET…

PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that masitinib…

PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, December 22, 2022, 6pm CET AB Science SA (Euronext -…

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF DEFICIENCY (NOD) FROM HEALTH CANADA FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AB SCIENCE HAS 90 CALENDAR DAYS TO RESPOND TO THE NOD Paris, December 13, 2022, 6pm…